Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

KEYTRUDA Met Primary Endpoint of EFS as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced SCCHN

October 15, 2024

Interim data from Ph 1 clinical study of misetionamide (GP-2250) in combination with gemcitabine in patients with pancreatic adenocarcinoma announced

October 15, 2024

Ph 1 results for Ribrecabtagene autoleucel (DRL-1801) from the SWASTH study in patients with R/R multiple myeloma announced

October 15, 2024

Ph 1 data supports further development of Lutetium (177Lu) rhPSMA-10.1 injection 

October 15, 2024

TALZENNA + XTANDI combo Prolongs OS in Ph 3 TALAPRO-2 Trial

October 15, 2024

Updated Ph 1b Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients announced; upcoming SUPRAME Ph 3 Trial to be registrational study

October 15, 2024

Autologous Dendritic Cell Vaccine DOC1021 Yields 93% 12-Month Survival for GBM Patients

October 8, 2024

ERLEADA® (apalutamide) demonstrates statistically significant and clinically meaningful improvement in OS compared to enzalutamide in patients with mCSPC

October 8, 2024

36-Month OS Rate of 84.4% in Locally Advanced Cervical Cancer Patients Treated with Versamune® HPV and Chemoradiation Announced 

October 8, 2024

Preliminary safety data from the Ph 1b portion of the BGBC016 study in 1L NSCLC patients announced

October 8, 2024

Positive Interim Ph 1 Results for P-BCMA-ALLO1 with High ORR in Heavily Pretreated RRMM Patients Reported

October 8, 2024

Interim Ph 2 Data for GRANITE Neoantigen Targeting Immunotherapy in 1L Metastatic MSS CRC Announced

October 8, 2024

Ph 1 Data of Concurrent Paxalisib + RT in Patients with Solid Tumor Brain Mets or Leptomeningeal Mets Harboring PI3K Pathway Mutations announced

October 8, 2024

PFS and OS announced from Ph 1 Study of MTX110 in Recurrent GBM

October 8, 2024

CARVYKTI significantly extends OS vs standard therapies for patients with multiple myeloma as early as second line

October 2, 2024

TALVEY + DARZALEX FASPRO combo shows deep and durable responses in RRMM patients 

October 2, 2024

DARZALEX FASPRO-based quadruplet regimen significantly improves MRD negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned

October 1, 2024

Positive Data Update from Ph 1 Clinical Trial of ELVN-001 in CML Announced

October 1, 2024

Significant New Data from Ph 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer Announced 

October 1, 2024

Initial Ph 2 Data of BDTX-1535 in Patients with Recurrent EGFRm NSCLC with Classical, Non-classical, and C797S Resistance Mutations Announced

October 1, 2024

MesoPher cell therapy increases 2-year RFS rate in resected pancreatic cancer by 50%

October 1, 2024

Positive Initial Safety, Tolerability, PK, and Preliminary Efficacy Data announced from Ph 1 Trial of PAS-004 in Advanced Cancer

October 1, 2024

TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) combo yields high response rates and durable responses in triple-class refractory RRMM patients

October 1, 2024

FAILED TRIAL: Ph 3 KEYFORM-007 trial of favezelimab + KEYTRUDA did not meet its primary endpoint of OS in patients with previously treated PD-L1+ve MSS mCRC

October 1, 2024

Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in PFS vs Chemo in Patients with Locally Advanced or Metastatic EGFR-Mutated NSCLC in HERTHENA-Lung02 Ph 3 Trial

September 24, 2024
Page1 … Page7 Page8 Page9 Page10 Page11 … Page30

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.